Sarepta Therapeutics, Inc. (SRPT) Market Cap & Valuation Ratios
Sarepta Therapeutics, Inc. (SRPT) has a market cap of $1.9B and a price-to-sales ratio of 0.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SRPTSarepta Therapeutics, Inc.Follow SRPT — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| SRPT | 1.9 | — | 1.0 | — | 4.4% | -20% | -7% | -8% |
| ZYME | 2.0 | — | 49.1 | — | -6.0% | -70% | -419% | — |
| RXRX | 2.0 | — | 26.4 | — | — | -15% | — | -136% |
| MRVI | 1.9 | — | 9.5 | — | -1.9% | -5% | -56% | -41% |
| SEPN | 1.9 | — | 15.3 | — | 5.6% | — | -44% | -18% |
| XNCR | 1.9 | — | 15.2 | — | -11.1% | -29% | -206% | -34% |
| MLYS | 1.8 | — | — | — | -7.6% | — | — | -73% |
| PVLA | 1.8 | — | — | — | — | — | — | -199% |
| TRVI | 1.8 | — | — | — | -2.9% | — | — | -34% |
| VIR | 1.8 | — | 4.2 | — | -11.4% | +1496% | -92% | -39% |
| ZBIO | 1.8 | — | — | — | -12.9% | -93% | — | -137% |
| Median of these 10 | — | 15.3 | — | -6.8% | -22% | -92% | -41% |
; EV/Sales 1.0 vs. 15.3.
Growth vs. price
each dot a company · hover or tap for valuesSarepta Therapeutics, Inc. — questions
- What is Sarepta Therapeutics, Inc.'s market cap?
- $1.9B.
- What is Sarepta Therapeutics, Inc.'s price-to-sales ratio?
- 0.9.
Every figure on this page comes from Sarepta Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.